

JUL. 14. 2003 5:09PM

DILWORTH PAXSON LLP

ATTORNEY DOCKET NO. 22253-69814

NO. 242 P. 14/38

USSN 09/943,688

RITA
JB
7/21/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Abdomohamad ROSTAMI *et al.*

Application No.: 09/943,688

Group Art Unit: 1265

Filed: 08/31/2001

Examiner: M.C. Flood

Title: Use of the Bowman Birk Inhibitor for the Treatment of Multiple Sclerosis and Other Autoimmune Diseases

Mail Stop FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE

This amendment and response is timely filed in response to the Office Action mailed December 3, 2002, and is accompanied by a request for a 3-month extension of time.

In the Specification:

Please amend the paragraph on page 3, beginning at line 1 to read as follows:

Absorbed BBI is measurable using antibodies to reduced BBI, produced by injection into experimental animals and utilized in immunoassays (Wan *et al.*, 1995). BBI has been assessed in the blood, tissue and urine of rodents and dogs after the ingestion of BBIC permitting pharmacokinetic studies, although it has not yet been feasible to measure BBI levels in the blood of humans after oral BBIC dosing. However, it has been found in the urine, starting within several hours after a single oral dose (Wan *et al.*, *Cancer Epidem. Biomarkers & Prevention* 8:601-608 (1999)). Of note, studies in orally-dosed animals have shown that some BBI can be subsequently found in the CNS even when the blood-brain barrier is intact (Kennedy, AR, personal communication).